Loading...
XSHG603658
Market cap3.13bUSD
Jan 17, Last price  
40.12CNY
1D
0.17%
1Q
-8.19%
Jan 2017
-27.83%
IPO
73.68%
Name

Autobio Diagnostics Co Ltd

Chart & Performance

D1W1MN
XSHG:603658 chart
P/E
18.84
P/S
5.16
EPS
2.13
Div Yield, %
2.09%
Shrs. gr., 5y
1.21%
Rev. gr., 5y
18.15%
Revenues
4.44b
+0.05%
211,844,562318,146,292409,364,583563,295,572716,488,576980,222,9751,400,142,0471,929,676,0262,679,435,6372,978,131,6053,765,916,9884,441,627,3594,443,655,727
Net income
1.22b
+4.28%
61,154,01796,122,497124,075,188208,221,070278,026,789349,758,059446,564,158562,570,893774,163,957747,793,833973,663,0741,167,437,1291,217,438,887
CFO
1.47b
-5.68%
50,592,60069,323,500103,223,692256,928,030308,630,046415,816,349481,731,392653,726,343842,886,756994,713,1531,461,234,8431,558,422,0461,469,855,864
Dividend
Jun 05, 20241.05208 CNY/sh
Earnings
May 09, 2025

Profile

Autobio Diagnostics Co., Ltd. engages in the research and development, production, and distribution of clinical diagnostic products. It develops immunoassay, biochemistry, microbiology, and IVD reagents; and instruments, such as automation and semi-automation systems, as well as medical laboratory solutions. The company's immunoassay products AutoLumo A2000 Plus, an automatic Chemiluminescence immunoassay analyzer; automatic microplate chemiluminescent enzyme immunoassay; and LUmo luminometers, PHOmo microplate readers, and iWO microplate washers. Its microbiology products comprise automated blood culture systems; blood culture bottles; AUTOMIC strips; and mycoplasma IES. The company was formerly known as Lifeclone Diagnostics Co., Ltd. and changed its name to Autobio Diagnostics Co., Ltd. in 2003. Autobio Diagnostics Co., Ltd. was founded in 1998 and is based in Zhengzhou, China. Autobio Diagnostics Co., Ltd. is a subsidiary of Zhengzhou Auto Industrial Co., Ltd.
URL
https://www.autobio.com.cn/
IPO date
Sep 01, 2016
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
4,443,656
0.05%
4,441,627
17.94%
Cost of revenue
2,579,873
3,103,383
Unusual Expense (Income)
NOPBT
1,863,783
1,338,244
NOPBT Margin
41.94%
30.13%
Operating Taxes
138,413
105,033
Tax Rate
7.43%
7.85%
NOPAT
1,725,369
1,233,211
Net income
1,217,439
4.28%
1,167,437
19.90%
Dividends
(479,118)
(418,936)
Dividend yield
1.45%
1.16%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
343,301
116,284
Long-term debt
49,271
32,518
Deferred revenue
30,984
30,815
Other long-term liabilities
90,912
73,175
Net debt
(4,251,291)
(1,005,493)
Cash flow
Cash from operating activities
1,469,856
1,558,422
CAPEX
(900,418)
Cash from investing activities
(787,221)
Cash from financing activities
(337,012)
FCF
4,110,434
1,271,194
Balance
Cash
4,520,557
1,137,622
Long term investments
123,306
16,674
Excess cash
4,421,680
932,214
Stockholders' equity
4,811,245
4,057,094
Invested Capital
4,734,483
7,086,684
ROIC
29.19%
17.49%
ROCE
19.80%
16.14%
EV
Common stock shares outstanding
579,733
583,719
Price
57.01
-7.83%
61.85
12.33%
Market cap
33,050,567
-8.45%
36,102,993
11.84%
EV
28,930,146
35,227,088
EBITDA
2,315,390
1,770,771
EV/EBITDA
12.49
19.89
Interest
24,542
21,231
Interest/NOPBT
1.32%
1.59%